Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS - Get Free Report) in a research note issued to investors on Tuesday. The firm set a "sell" rating on the biotechnology company's stock.

Separately, Barclays lowered their price objective on shares of Cellectis from $7.00 to $5.00 and set an "overweight" rating for the company in a research note on Tuesday, November 5th.

Cellectis Trading Down 1.1 %

CLLS traded down $0.02 during trading on Tuesday, reaching $1.80. 384,058 shares of the stock traded hands, compared to its average volume of 55,909. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The stock's 50-day moving average is $1.84 and its 200 day moving average is $2.02. Cellectis has a 12 month low of $1.41 and a 12 month high of $3.38. The stock has a market capitalization of $100.05 million, a PE ratio of -1.38 and a beta of 3.09.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The business had revenue of $18.05 million for the quarter, compared to the consensus estimate of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same quarter in the previous year, the company earned ($0.31) EPS. Equities analysts anticipate that Cellectis will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Cellectis

Large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new position in shares of Cellectis in the second quarter worth about $29,000. First Affirmative Financial Network purchased a new position in Cellectis in the 3rd quarter worth approximately $45,000. Principal Financial Group Inc. lifted its position in Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company's stock valued at $817,000 after purchasing an additional 12,467 shares during the last quarter. Finally, Long Focus Capital Management LLC boosted its stake in shares of Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company's stock valued at $8,634,000 after purchasing an additional 130,000 shares during the period. Hedge funds and other institutional investors own 63.90% of the company's stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.